Successful Acquisitions Require Careful Integration Planning – Cytyc VP
This article was originally published in The Gray Sheet
Executive Summary
Acquisition failure rates hovering around the 80% level signal the need for greater attention to integration planning, according to James McDonough, senior vice president of corporate development & operations at Cytyc
You may also be interested in...
Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry
Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9
Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.